Xconomy | Seattle - Business + Technology in the Exponential Economy

Seattle Genetics Gets Milestone

Seattle Genetics (NASDAQ: SGEN) said today that it achieved a milestone under its partnership with Bayer Schering Pharma AG of Germany. The Bothell, WA-based company provided Bayer with a license to its technology for linking antibodies to toxins, with a goal of making targeted and potent anti-cancer drugs. Bayer has now submitted an application to the FDA to start a clinical trial of a drug using the technology, Seattle Genetics said. Financial terms of the agreement weren’t disclosed.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: